Wonmet G2 Tablet PR contains a combination of Glimepiride 2mg and Metformin 500mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The combination of these two agents provides complementary mechanisms of action, resulting in improved glycemic control in patients inadequately controlled by diet and exercise alone. Wonmet G2 Tablet PR is indicated for adults with type 2 diabetes who require dual therapy to achieve target blood glucose levels. It is important to administer this medication with meals to reduce gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Hypoglycemia is a potential adverse effect due to Glimepiride, and patients should be educated on recognizing symptoms and managing episodes appropriately. Wonmet G2 Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular medical supervision.